跳至主要内容
临床试验/2024-516667-91-00
2024-516667-91-00招募中4 期

The effect of oral buspirone hydrochloride on esophageal motility, bolus transit and symptoms of dysphagia, in patients with poor esophageal motility: A randomized, double-blind, placebo controlled, cross-over trial with high resolution esophageal manometry and impedance.

UZ Leuven1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年10月24日最近更新:
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
UZ Leuven
入组人数
25
试验地点
1
主要终点
Change in distal contractile integral (DCI, mm Hg*s*cm) between buspirone and placebo established on high resolution impedance manometry (HRiM), for the liquid bolus (5 mL) in supine position.

研究概览

简要总结

To investigate the effect of buspirone on high-resolution manometry parameters (specifically: distal contractile integral, DCI) in patients with poor esophageal motility during a high resolution impedance manometry with 3 types of boluses (on liquid bolus, 5mL, in supine position)

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Ineffective motility or absent contractility identified on HRiM
  • Primary complaint of dysphagia for a minimum of 2 months
  • Age > 18 years
  • No anatomical cause for symptoms
  • No hiatal hernia ≥3 cm
  • Sexually active women of childbearing potential participating in the study must be using an appropriate form of contraception.

排除标准

  • Endoscopic signs of severe erosive esophagitis (grade C or D, Los Angeles classification) on endoscopy performed off PPI treatment in the 12 months prior to screening, or ≥ grade B when endoscopy is performed during PPI treatment.
  • Major psychiatric disorder.
  • Pregnancy or breastfeeding.
  • History of poor compliance.
  • History of/or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent.
  • History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
  • Systemic diseases, known to affect esophageal motility (i.e. systemic sclerosis)
  • Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed).
  • Hiatal hernia ≥3 cm
  • QT c>450 ms.
  • Use of medication that effect cholinergic function such as anticholinergics, tricyclic antidepressants.
  • Concomitant promotility agents such as prucalopride or domperidone.
  • Concomitant use of more than one benzodiazepine.
  • Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator.

结局指标

主要结局

Change in distal contractile integral (DCI, mm Hg*s*cm) between buspirone and placebo established on high resolution impedance manometry (HRiM), for the liquid bolus (5 mL) in supine position.

Change in distal contractile integral (DCI, mm Hg*s*cm) between buspirone and placebo established on high resolution impedance manometry (HRiM), for the liquid bolus (5 mL) in supine position.

次要结局

  • Change in symptoms between placebo and buspirone during the HRiM with 3 types of boluses: A Likert score applied during all swallows: 1 (Normal), 2 (Slow passage of bolus), 3 (Stepwise passage), 4 (Partial Blockage), 5 (Complete Blockage)
  • Proximal Contractile Integral (PCI es., mmHg.s.cm)
  • Distal Contractile Integral (DCI, mmHg.s.cm)
  • Largest Break Size (cm)
  • Distal Latency (DL, s)
  • Integrated Relaxation Pressure 4s (IRP4s, mmHg)
  • Pressure Flow Index (PFI)
  • Impedance Ratio (IR)
  • Distension Pressure Accommodation (DPA, mmHg)
  • Distension Pressure Emptying (DPE, mmHg)
  • Ramp Pressure (RP, mmHg/s)
  • Contractile Segment Impedance (CSI, Ohms)
  • Bolus Presence Time (BPT, s)
  • Bolus Flow Time (BFT, s)
  • Esophago-Gastric Junction Resting Pressure (EGJ Rest.P, mmHg)
  • Esophago-Gastric Junction Contractile Integral (EGJCI, mmHg.cm)
  • Lower Esophageal Sphincter – Crural Diaphragm (LES-CD, mm)
  • Mayo Dysphagia Questionnaire
  • Overall Treatment Evaluation
  • Overall Symptom Severity

研究者

发起方
UZ Leuven
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Jan Tack

Scientific

UZ Leuven

研究点 (1)

Loading locations...

相似试验